TG Therapeutics (TGTX)
(Delayed Data from NSDQ)
$17.18 USD
+0.67 (4.06%)
Updated May 7, 2024 04:00 PM ET
After-Market: $17.15 -0.03 (-0.17%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Brokerage Reports
TG Therapeutics, Inc. [TGTX]
Reports for Purchase
Showing records 201 - 220 ( 275 total )
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
1101/Imbruvica; What a Pair; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
''1202 Profile Keeps Getting Better; We Think Differentiation Clear
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Breaking Further Ground; ''1202 / Imbruvica Combo; Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
3Q14 Update - Two Stars on Show at ASH Shooting for Phase 3 and Beyond
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: TG Therapeutics, Inc.
Industry: Medical - Products
3Q14 Results; Expect Strong Showing at ASH; Imminent Start to Phase III
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
ASH Abstracts Priming a Successful Meeting, in our View; Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
The Positive ''1202 Chess Moves Continue; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
A+ For Projected Phase III Cost Efficiencies; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
SPA, TG-1101 and Imbruvica; Nice Combination; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Nice PI3K Deal for INFI; TGTX Has Strong Leverage with ''1202
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.